Intraoperative Low-dose Ketamine Infusion for Patients With Obstructive Sleep Apnea

Model scores of the 29,894 trials active now.

Model score 11% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (112 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-09-12. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: postoperativeoxygenreduceassociatedinfusion
  Phrases that lowered it: the aimpatients withaim ofagedgeneral
• Sponsor's past termination rate: 12.6% (raises risk) · Sponsor's track record
• Primary purpose: prevention (lowers risk) · Design
• Maximum age: 100 (lowers risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 19 (lowers risk) · Who can join
• Has a data monitoring committee: Yes (raises risk) · Design
• Blinding: triple (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 91 (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 17.2% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Disease area, respiratory: Yes (raises risk) · Disease area
• Drug's FAERS reports marked serious: 93.4% (raises risk) · Drug's FDA history
• Responsible party: principal investigator (lowers risk) · Design
• Number of arms: 2 (raises risk) · Design
• Drug's FAERS reports before start: 2431 (raises risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• The Impact of Ketamine on Postoperative Cognitive Dysfunction, Delirium, and Renal Dysfunction NCT02554253 · started 2015 · scored riskier than 82% of active trials completed
• Ketamine and Closed-Loop Anesthesia System NCT02011347 · started 2013 · scored riskier than 47% of active trials terminated
• Perioperative Ketamine for Pain With Gastric Bypass NCT03448068 · started 2018 · scored riskier than 94% of active trials completed
• Efficacy of Opioid-free Anesthesia in Reducing Postoperative Respiratory Depression in Children Undergoing Tonsillectomy NCT02987985 · started 2017 · scored riskier than 15% of active trials completed
• The Effect of Low Dose Intra-operative Ketamine on Closed-loop Controlled General Anesthesia NCT03009409 · started 2018 · scored riskier than 13% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.